Jiang Rensheng Net Worth

Jiang Rensheng has an estimated net worth of $4.8 billion, according to Forbes Real-Time Billionaires, Jiang Rensheng profile (figures as of October 20, 2026). That is down from a peak of $24.4 billion.

Jiang Rensheng is a Chinese businessman and the chairman of Chongqing Zhifei Biological Products, a Shenzhen-listed vaccine company. Forbes describes him as self-made.

His path into business was unusual. He started work as a primary school teacher and then became a government health official, which gave him an inside view of China's public health system, before he left to start his own company.

Jiang is married with one child and lives in Chongqing, the inland city where Zhifei is based. He keeps a relatively low profile for someone with such a large fortune.

Jiang's career shows how knowledge of the health system can become a business. His years as a health official taught him how vaccines are bought and delivered in China, and he built a company that sits between global drug makers and the Chinese market while also developing its own products.

How Jiang Rensheng made his money

Zhifei grew by making and distributing vaccines in China. It has been a longtime distribution partner of Merck, and in 2018 it won the Chinese sales rights to Merck's HPV vaccine, which became one of its biggest products.

The company's shares rose sharply in 2020, rising 80% in June after it won approval to start human trials of a COVID-19 vaccine. That rally made Jiang one of the richest people in China for a time.

He has kept building. In 2023 he took his antibody drug maker, Chongqing Genrix Biopharmaceutical, public on the Shanghai Stock Exchange. In 2024 Zhifei signed an exclusive deal with GSK to distribute its shingles vaccine and sell its RSV vaccines in China.

Vaccine demand in China is huge, and partnerships with large Western drug makers gave Zhifei access to products that Chinese families wanted. The company built a large sales network to reach clinics and hospitals across the country. That network is what makes it valuable to foreign partners such as Merck and GSK.

How Forbes has valued Jiang Rensheng

Forbes valued Jiang at $4.9 billion in 2019 and $7.6 billion in 2020. His figure soared to $24.4 billion in 2021, at the peak of the vaccine stock boom.

It has fallen every year since: $17.7 billion in 2022, $12.2 billion in 2023, $10.9 billion in 2024, $6.3 billion in 2025 and $5.5 billion on the 2026 World's Billionaires List. As of October 20, 2026, the Forbes real-time billionaires tracker showed $4.8 billion, about a fifth of his 2021 peak.